An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis - BARRAD
Latest Information Update: 09 Mar 2026
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms BARRAD
Most Recent Events
- 09 Mar 2026 New trial record